American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

M. Elizabeth H Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan Lester, Richard Love, Pamela B. Mangu, Lisa McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony RhodesHironobu Sasano, Jared N. Schwartz, Fred C G Sweep, Sheila Taube, Emina Emilia Torlakovic, Paul Valenstein, Giuseppe Viale, Daniel W Visscher, Thomas Wheeler, R. Bruce Williams, James L. Wittliff, Antonio C. Wolff

Research output: Contribution to journalArticle

1639 Citations (Scopus)

Abstract

Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)2784-2795
Number of pages12
JournalJournal of Clinical Oncology
Volume28
Issue number16
DOIs
StatePublished - Jun 1 2010

Fingerprint

Medical Oncology
Progesterone Receptors
Estrogen Receptors
Guidelines
Breast Neoplasms
Ontario
Pathologists
Neoplasms
Randomized Controlled Trials
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. / Hammond, M. Elizabeth H; Hayes, Daniel F.; Dowsett, Mitch; Allred, D. Craig; Hagerty, Karen L.; Badve, Sunil; Fitzgibbons, Patrick L.; Francis, Glenn; Goldstein, Neil S.; Hayes, Malcolm; Hicks, David G.; Lester, Susan; Love, Richard; Mangu, Pamela B.; McShane, Lisa; Miller, Keith; Osborne, C. Kent; Paik, Soonmyung; Perlmutter, Jane; Rhodes, Anthony; Sasano, Hironobu; Schwartz, Jared N.; Sweep, Fred C G; Taube, Sheila; Torlakovic, Emina Emilia; Valenstein, Paul; Viale, Giuseppe; Visscher, Daniel W; Wheeler, Thomas; Williams, R. Bruce; Wittliff, James L.; Wolff, Antonio C.

In: Journal of Clinical Oncology, Vol. 28, No. 16, 01.06.2010, p. 2784-2795.

Research output: Contribution to journalArticle

Hammond, MEH, Hayes, DF, Dowsett, M, Allred, DC, Hagerty, KL, Badve, S, Fitzgibbons, PL, Francis, G, Goldstein, NS, Hayes, M, Hicks, DG, Lester, S, Love, R, Mangu, PB, McShane, L, Miller, K, Osborne, CK, Paik, S, Perlmutter, J, Rhodes, A, Sasano, H, Schwartz, JN, Sweep, FCG, Taube, S, Torlakovic, EE, Valenstein, P, Viale, G, Visscher, DW, Wheeler, T, Williams, RB, Wittliff, JL & Wolff, AC 2010, 'American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer', Journal of Clinical Oncology, vol. 28, no. 16, pp. 2784-2795. https://doi.org/10.1200/JCO.2009.25.6529
Hammond, M. Elizabeth H ; Hayes, Daniel F. ; Dowsett, Mitch ; Allred, D. Craig ; Hagerty, Karen L. ; Badve, Sunil ; Fitzgibbons, Patrick L. ; Francis, Glenn ; Goldstein, Neil S. ; Hayes, Malcolm ; Hicks, David G. ; Lester, Susan ; Love, Richard ; Mangu, Pamela B. ; McShane, Lisa ; Miller, Keith ; Osborne, C. Kent ; Paik, Soonmyung ; Perlmutter, Jane ; Rhodes, Anthony ; Sasano, Hironobu ; Schwartz, Jared N. ; Sweep, Fred C G ; Taube, Sheila ; Torlakovic, Emina Emilia ; Valenstein, Paul ; Viale, Giuseppe ; Visscher, Daniel W ; Wheeler, Thomas ; Williams, R. Bruce ; Wittliff, James L. ; Wolff, Antonio C. / American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 16. pp. 2784-2795.
@article{c9480d542bab4cf88e3da89f7c637875,
title = "American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer",
abstract = "Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20{\%} of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1{\%} positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.",
author = "Hammond, {M. Elizabeth H} and Hayes, {Daniel F.} and Mitch Dowsett and Allred, {D. Craig} and Hagerty, {Karen L.} and Sunil Badve and Fitzgibbons, {Patrick L.} and Glenn Francis and Goldstein, {Neil S.} and Malcolm Hayes and Hicks, {David G.} and Susan Lester and Richard Love and Mangu, {Pamela B.} and Lisa McShane and Keith Miller and Osborne, {C. Kent} and Soonmyung Paik and Jane Perlmutter and Anthony Rhodes and Hironobu Sasano and Schwartz, {Jared N.} and Sweep, {Fred C G} and Sheila Taube and Torlakovic, {Emina Emilia} and Paul Valenstein and Giuseppe Viale and Visscher, {Daniel W} and Thomas Wheeler and Williams, {R. Bruce} and Wittliff, {James L.} and Wolff, {Antonio C.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1200/JCO.2009.25.6529",
language = "English (US)",
volume = "28",
pages = "2784--2795",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

AU - Hammond, M. Elizabeth H

AU - Hayes, Daniel F.

AU - Dowsett, Mitch

AU - Allred, D. Craig

AU - Hagerty, Karen L.

AU - Badve, Sunil

AU - Fitzgibbons, Patrick L.

AU - Francis, Glenn

AU - Goldstein, Neil S.

AU - Hayes, Malcolm

AU - Hicks, David G.

AU - Lester, Susan

AU - Love, Richard

AU - Mangu, Pamela B.

AU - McShane, Lisa

AU - Miller, Keith

AU - Osborne, C. Kent

AU - Paik, Soonmyung

AU - Perlmutter, Jane

AU - Rhodes, Anthony

AU - Sasano, Hironobu

AU - Schwartz, Jared N.

AU - Sweep, Fred C G

AU - Taube, Sheila

AU - Torlakovic, Emina Emilia

AU - Valenstein, Paul

AU - Viale, Giuseppe

AU - Visscher, Daniel W

AU - Wheeler, Thomas

AU - Williams, R. Bruce

AU - Wittliff, James L.

AU - Wolff, Antonio C.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.

AB - Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=77954526150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954526150&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.6529

DO - 10.1200/JCO.2009.25.6529

M3 - Article

C2 - 20404251

AN - SCOPUS:77954526150

VL - 28

SP - 2784

EP - 2795

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -